Table 1.
Baseline characteristics and Initial Treatment of first national program patients initiated on HAART between January and July 2002 (N=633)
| Age, Median (IQR)in years | 34.8 (30.2 – 41.3) |
| Female, Number (%) | 378 (59.88) |
| Weight, mean (kg) | 52.3 |
| BMI, mean | 18.8 |
| BMI< 18.5, Number (%) | 219 (35) |
| CD4 cell count, Median (IQR) | 67 (28–127) |
| HIV-1 plasma RNA, Median (copies/mL) | 444,000 (173,000–750,000) |
| Karnofsky score | 80.4 |
| Mean ≤60, Number (%) | 55 (9) |
| Hemoglobin, Mean, g/dl | 10.7 |
| Hemoglobin <8 g/dL, Number (%) | 62 (9.8) |
| WHO stage at entry, Number (%) | 606 (95.5) |
| I | 18 (3) |
| II | 74 (12) |
| III | 271 (43) |
| IV | 243 (38) |
| Opportunistic Infections n, (%) | |
| Wasting Syndrome | 407 (64) |
| Pulmonary TB | 244 (39) |
| Extrapulmonary TB | 42 (7) |
| Herpes Zoster | 110 (17) |
| Papular pruritic dermatitis/eosinophilic folliculitis | 106 (17) |
| Chronic diarrhea | 103 (16) |
| Esophageal candidiasis | 48 (8) |
| Kaposis’s sarcoma | 46 (7) |
| Pneumocystis jiroveci pneumonia (PJP) | 39 (6) |
| Cryptococcal Meningitis | 33 (5) |
| AIDS Dementia | 29 (5) |
| Cytomegalovirus (CMV) retinitis | 14 (2) |
| Initial ART regimen n, (%) | |
| CBV / NVP | 281(44.4) |
| CBV / EFV | 320 (50.6) |
| d4T / 3TC / NVP | 15 (2.4) |
| d4T / 3TC / EFV | 11(1.7) |
| d4T / ddI / NVP | 2 (0.3) |
| d4T / ddI / EFV | 4(0.8) |